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Myotonic dystrophy type I (DM1) is a disabling neuromuscu-
lar disease with no causal treatment available. This disease is
caused by expanded CTG trinucleotide repeats in the 3UTR of
the dystrophia myotonica protein kinase gene. On the RNA
level, expanded (CUG)n repeats form hairpin structures that
sequester splicing factors such as muscleblind-like 1 (MBNL1).
Lackof availableMBNL1 leads tomisregulated alternative splic-
ing of many target pre-mRNAs, leading to the multisystemic
symptoms in DM1. Many studies aiming to identify small mol-
ecules that target the (CUG)n-MBNL1 complex focused on syn-
thetic molecules. In an effort to identify new small molecules
that liberate sequesteredMBNL1 from(CUG)nRNA,we focused
specifically on small molecules of natural origin. Natural prod-
ucts remain an important source for drugs and play a significant
role in providing novel leads and pharmacophores formedicinal
chemistry. In a new DM1 mechanism-based biochemical assay,
we screened a collection of isolated natural compounds and a
library of over 2100 extracts from plants and fungal strains.
HPLC-based activity profiling in combination with spectro-
scopicmethods were used to identify the active principles in the
extracts. The bioactivity of the identified compounds was inves-
tigated in a human cellmodel and in amousemodel ofDM1.We
identified several alkaloids, including the -carboline harmine
and the isoquinoline berberine, that ameliorated certain aspects
of theDM1pathology in thesemodels. Alkaloids as a compound
class may have potential for drug discovery in other RNA-medi-
ated diseases.
Myotonic dystrophy type I (DM1)4 is the most common
muscular dystrophy in the adult population, with a relatively
high prevalence of about 1:8000 (1). This autosomal domi-
nantly inherited disease affects multiple organs, most promi-
nently the skeletal muscle, with wasting, weakness, and an
inability to relax (myotonia) (1). Currently, there is no effective
treatment for this disabling disease. The pathomechanism of
DM1 is linked to a CTGn expansion in the 3 UTR of the dys-
trophia myotonica protein kinase (DMPK) gene (2, 3), leading
to a toxic gain-of-functionRNA (4, 5). ThemutantDMPK tran-
script is entrappedwithin nuclei of affected cells, where it forms
aggregates (foci) with splicing factors such as muscleblind-like
1 (MBNL1) (6, 7). Bound to mutant DMPK (CUG)n RNA,
MBNL1 is no longer available for correct splicing of its target
pre-mRNAs (8, 9). Thus, the splicing of a multitude of
pre-mRNAs is misregulated, including the skeletal muscle
chloride channel (CLCN1), the insulin receptor (INSR), sarco-
plasmic/endoplasmic reticulumCa2ATPase 1 (SERCA1), and
cardiac troponin T type 2 (TNNT2) pre-mRNA (10–16). Inter-
estingly, the missplicing of some pre-mRNAs can be linked
directly to a certain disease symptom, e.g.myotonia in the case
of the CLCN1 pre-mRNA. MBNL1 sequestration by (CUG)n
RNAcauses inclusion of alternative exon 7a, leading to a shift in
the open reading frame and to premature termination of trans-
lation (12, 13). As a result, functional CLCN1 protein is
decreased, which leads to the myotonia characteristic of DM1
(17).
To date, most therapeutic strategies toward DM1 focused
either on the development of agents degrading the toxic RNA
or blocking its pathogenic interaction with proteins; these
strategies are reviewed in Ref. 18. Antisense oligonucleotides
targeting the DMPK-(CUG)n transcripts (5, 19) and viral over-
expression ofMBNL1 (20) have been shown to reverse the toxic
RNA effect in vitro and in vivo. Compared with the antisense
oligonucleotide and gene therapy approaches, an advantage of a
suitable small molecule is its potential to penetrate all tissues
affected in DM1 patients and its potential oral bioavailability. A
variety of small molecules have been described that inhibit
the (CUG)n-MBNL1 complex and improve DM1-associated
molecular defects in vitro and in some cases also in vivo. Several
approacheswere successful in identifying smallmolecules, such
as screening of known nucleic acid binders (21), rational design
of small molecules based on the structure of (CUG)n RNA (22),
rational design of oligomers of (CUG)n RNA binders by modu-
lar assembly (23, 24), combinatorial chemistry (25, 26), and
high-throughput screening (27, 28).
* This work was funded by the Neuromuscular Research Association Basel,
Swiss National Science Foundation, andbyMyosuisse. The authors declare
that they have no conflicts of interest with the contents of this article.
1 Supported by Swiss Federal Commission for Scholarship for Foreign Stu-
dents (FCS) and South African National Research Foundation fellowships.
2 To whom correspondence may be addressed: Neuromuscular Research
Group, Depts. of Neurology and Biomedicine, University Hospital Basel,
Klingelbergstr. 50, 4056 Basel, Switzerland. Tel.: 41-61-2671635; E-mail:
j.kinter@unibas.ch.
3 To whom correspondence may be addressed: Neuromuscular Research
Group, Depts. of Neurology and Biomedicine, University Hospital Basel,
Klingelbergstr. 50, 4056 Basel, Switzerland. Tel.: 41-61-2652525; E-mail:
michael.sinnreich@unibas.ch.
4 The abbreviations used are: DM1, myotonic dystrophy type 1; DMPK, dys-
trophia myotonica protein kinase; HSALR, human skeletal -actin long
repeat; qPCR, quantitative PCR; DHB, dihydroberberine; GM, growth
medium.
crossmark
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 291, NO. 33, pp. 17165–17177, August 12, 2016
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
AUGUST 12, 2016•VOLUME 291•NUMBER 33 JOURNAL OF BIOLOGICAL CHEMISTRY 17165
 at U
niversitaetsbibliothek M
edizin on N
ovem
ber 28, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Most of the described (CUG)n RNA-targeting molecules are
synthetic. Only a few small molecules of natural origin have
been described, such as neomycin B (21) and lomofungin (27).
To our knowledge, our study is the first to focus on small mol-
ecules of natural origin and represents the first screening of
natural extracts in DM1 drug discovery. As RNA is still a rela-
tively unexploited drug target, natural products present a rich
source of new and diverse RNA binders (29). Interestingly,
many known RNA-binding drugs are of natural origin, such as
antibiotics that target the bacterial ribosomal RNA (30). Hence,
it is of interest to investigate natural products in drug discovery
for RNA-mediated diseases such as DM1.
We describe here the screening of isolated natural com-
pounds and extracts from plants and fungal strains in a novel
CUG78-MBNL1 complex inhibition assay. We identified sev-
eral alkaloids as CUG78-MBNL1 complex inhibitors. Testing
their bioactivity in a humanmyoblastmodel of DM1 (31) and in
the human skeletal -actin long repeat (HSALR) mouse model
of DM1 (4) showed that the alkaloids ameliorate certain aspects
of the DM1 pathology.
Results
CUG78-MBNL1 Complex Inhibitors of Natural Origin—A
collection of 70 isolated natural compounds and a library con-
taining 2128 extracts from plants and fungi were screened with
a novel in vitro CUG78-MBNL1 complex inhibition assay (Fig.
1a). Biotinylated CUG78 RNA was immobilized on Neutr-
Avidin-coated plates that were then co-incubated with
MBNL1-HIS and compounds or extracts. The plates were
washed to remove unbound components, and MBNL1-HIS in
complex with immobilized CUG78 RNA was detected via an
anti-HIS and a secondary HRP-conjugated antibody. The
library of isolated natural compounds was screened at 100 M
concentration and led to the identification of the isoquinoline
alkaloid berberine (Fig. 1b) as a complex formation inhibitor
with an IC50 of 86.3 5.8 M (Fig. 1c). Another alkaloid, isain-
digotone, showedweak inhibitory activity at 100Mconcentra-
tion. From the extract library we identified 21 extracts that
inhibited CUG78-MBNL1 complex formation by 40–82% at a
concentration of 100 g/ml compared with solvent-only con-
trols. Seven extracts were chosen for fractionation. To identify
the active principles in these extracts, we used an approach
referred to as HPLC-based activity profiling. It combines the
separation of complex mixtures with spectroscopic data
recorded online and with biological information obtained in
parallel from time-based microfractionation and a subsequent
bioassay (32). In addition, offlinemicroprobeNMRanalysiswas
used to fully establish the structure of active compounds. The
alkaloid harmine (Fig. 1b) was identified as an active constitu-
ent in amethanolic extract from the roots of Peganumharmala
(Nitrariaceae) (Fig. 2a). Besides, two closely related diterpene-
quinones, methylenetanshinquinone and 1,2-dihydrotanshin-
quinone,were detected in the active fractions of an ethyl acetate
extract from roots of Salvia miltiorrhiza (Lamiaceae) (Fig. 2b).
A commercial sample of harmine had an IC50 of 132.4 9.3M
(Fig. 1c), whereas the two diterpenequinones, also commer-
cially obtained, showed weak inhibitory activity at 100 M con-
centration. The inhibitory activity of the remaining extracts
could be assigned to tannins. These extracts lost their complex
inhibitory effect after filtration through a polyamide cartridge
to remove polyphenolic tannins.
The alkaloids berberine and harminewere chosen for further
study.We tested a small set of structural analogues of berberine
and identified coralyne (Fig. 1b), a planar berberine derivative,
as a stronger CUG78-MBNL1 complex inhibitor with an IC50 of
17.8  0.2 M (Fig. 1, b and c). As reference compounds,
Hoechst 33258 and neomycin B, two known nucleic acid bind-
FIGURE 1. Screening for small molecules of natural origin that disrupt the CUG78-MBNL1 complex in vitro. a, the CUG78-MBNL1 inhibition assay detects
the amount of MBNL1 bound to CUG78-RNA. b, structure of the identified alkaloids berberine, coralyne, and harmine. c, CUG78-MBNL1 complex inhibition
curves. OD, optical density; TMB, 3,3,5,5-tetramethylbenzidine.
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ers, were tested and had IC50 values of 195.5 3.0M and 5.3
0.6 M, respectively.
Identified Alkaloids Improve Splicing in Human DM1
Myoblasts—The alkaloids identified in our in vitro screening
assay were tested for their ability to ameliorate splicing in a
human DM1myoblast cell line containing a CTG1300 repeat in
the 3 UTR of the DMPK gene (31). The WT control cell line
contained a normal repeat length in the same locus. Differenti-
ated DM1myoblasts were treated with the identified alkaloids,
and alternative splicing was analyzed by a quantitative PCR
(qPCR) method using two primer pairs. This method allowed
real-time quantitation of the inclusion/exclusion of an investi-
gated alternatively spliced exon.
Berberine improved the splicing of the TNNT2 pre-mRNA
exon 5. In 80Mberberine-treatedDM1myoblasts, the splicing
was close to that of the WT control myoblasts. TNNT2
pre-mRNA splicing was rescued by 62.1%  3.2% (p  0.001,
Student’s t test, 20 M), 75.1% 2.8% (p 0.0006, 40 M), and
86.2% 0.8% (p 0.0003, 80M) through berberine treatment
(Fig. 3a). However, berberine treatment had a negative effect on
INSR pre-mRNA exon 11 splicing (Fig. 3a) in DM1 myoblasts.
In contrast to berberine, harmine improved both the splicing of
the TNNT2 pre-mRNA exon 5 by 53.3% 3.5% (p 0.003, 20
M), 76.8% 1.6% (p 0.0005, 40M), and 66.1% 1.2% (p
0.0009, 80 M), and, furthermore, the splicing of the INSR
pre-mRNA exon 11 by 6.3%  0.3% (p  0.003, 40 M) and
55.4%  3.3% (p  0.0003, 80 M) (Fig. 3, a and b). The alter-
native splicing results obtained with the qPCR method for
berberine and harmine were confirmed with classical RT-
PCR and visualization of two alternatively spliced isoforms
of the INSR and TNNT2 pre-mRNA on 3% agarose gels (Fig.
3, c and d). The synthetic berberine derivative coralyne and
the two diterpenequinones, identified together with harmine
during the extract screening, showed no effect on splicing in
the DM1 cell model.
To investigate the selectivity of berberine and harmine, we
tested their effect on alternative splicing of two genes known to
be alternatively spliced but independent of MBNL1, i.e. ATE1
and FHL1 (Fig. 3, e and f) (33).We analyzed exon 7 inclusion in
theATE1 pre-mRNA, which was close to 33% for theWT cell
line and close to 40% in the DM1 cell line. Exon 5 inclusion in
the FHL1 pre-mRNA was close to 0.1–0.2% for both the WT
and the DM1 cell line. The levels of alternative exon inclu-
sion in berberine- and harmine-treated (both at 20 M and
80 M) myoblasts were in the range of the levels of vehicle-
treated WT and DM1 control myoblasts. The qPCR analysis
of the harmine effect on TNNT2 pre-mRNA alternative
splicing in WT myoblasts showed an enhancement of
MBNL1-dependent splicing analogous to harmine-treated
DM1 myoblasts. This effect, however, was only observed
with the qPCR method and not visible by the classical RT-
PCR method (Fig. 3, b and d).
The cellular toxicity of berberine and harmine was deter-
mined in a viability assay with C2C12 mouse myoblasts. Con-
centrations (toxicity IC50) were determined at which half of the
myoblasts remained viable after 2 days of compound incuba-
tion. Berberine yielded a toxicity IC50 of 212.1  18.3 M and
harmine one of 123.3 4.6 M. Mitomycin C was measured as
reference compound with a toxicity IC50 of 20.4  1.6 M.
Although the IC50 and toxicity IC50 values were relatively close
for both alkaloids, both compounds showed an effect on alter-
native splicing in the myoblast model at concentrations signif-
icantly lower than the IC50 and toxicity IC50 values, e.g. at 20M
(Fig. 3).
Harmine Reduces Focus Formation in Human DM1
Myoblasts—To examine whether the alkaloids berberine and
harmine reduce the sequestration of MBNL1 by (CUG)n RNA,
focus formation was investigated in the two human myoblast
cell lines. Immunofluorescence staining in both the WT (nor-
FIGURE 2. a, HPLC-based activity profiling of the P. harmalamethanol extract.
Shown on the y axis are the online HPLC-UV trace at 254 nm (black) and the
A450 signal from the CUG78-MBNL1 inhibition assay (red). The x axis shows the
time inminutes. 29 fractions were collected, 1 min each. The inhibitory activ-
ity of the fraction atminutes 8–9was assigned to the alkaloid harmine. Based
on online MS and UV spectroscopic data, the other major peak eluting at 6.6
minwas assigned toharmol. Theactivity in theearly-eluting fraction, 2–3min,
did not correspond to any UV peak and was not further investigated. OD,
optical density; mAU, milli absorbance units. b, HPLC-based activity profiling
of the ethyl acetate extract of S. miltiorrhiza. The inhibitory activity of the
fraction at minutes 26–27 was assigned to two diterpenequinone isomers,
1,2-dihydrotanshinquinone and methylenetanshinquinone.
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FIGURE 3. Representative qPCR splicing data for WT and DM1 control myoblasts and treated human myoblasts. The percentage of alternative exon
inclusion is shown.a, berberine improves the splicingof the TNNT2pre-mRNAbut has a detrimental effect on the INSRpre-mRNA splicing.b, harmine improves
the splicingof both the TNNT2 andof the INSRpre-mRNA.Harmine also promotesMBNL1-dependent splicing in treatedWTmyoblasts, as shown for the TNNT2
pre-mRNA. c and d, RT-PCR analysis of INSR and TNNT2 pre-mRNA alternative splicing. Visualized on 3% agarose are two alternative splicing isoforms for both
pre-mRNAs in untreated WT and DM1 control myoblasts and DM1 myoblasts treated with (c) berberine and (d) harmine. The harmine effect on MBNL1-de-
pendent splicing in treated WT myoblasts was not visible with this method, as shown for the TNNT2 pre-mRNA. e and f, berberine and harmine do not affect
alternative splicing of MBNL1-independently regulated ATE1 and FHL1 pre-mRNAs in treated DM1myoblasts compared with untreated WT and DM1 control
myoblasts. **, p 0.01; ***, p 0.001; ****, p 0.0001.
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mal CUG repeat length) and the DM1 (CUG1300) cell line
showed that MBNL1 was mainly localized to the nuclei. In the
DM1 cells, punctate staining of MBNL1 within the nucleus
could be co-localized in foci with (CUG)n RNA, visualized by
fluorescence in situ hybridization. Treatment with 80 M
harmine significantly reduced (p 0.00005, Student’s t test) the
quantity of foci in DM1myoblasts (Fig. 4a) to 0.9 0.2 foci per
nucleus compared with DMSO-treated DM1 myoblasts with
4.7  0.3 foci per nucleus (Fig. 4, a and b). Harmine-treated
myoblasts lost their punctate nuclear MBNL1 staining,
indicative of MBNL1 release from the toxic (CUG)n RNA,
although the nuclear MBNL1 staining pattern of WT myo-
blasts was not regained. We analyzed by Western immuno-
blotting whether treatment with harmine reduced the levels
FIGURE 4.Analysis of foci with FISH and immunofluorescence. a, harmine reduces the amount of foci at 80M concentration, whereas berberine does not
reduce foci. For each condition, (CUG)n RNA staining (red), MBNL1 staining (green), and a merge of both with nuclear DAPI staining (blue) is shown. Vehicle-
treated controlWT andDM1myoblasts and compound-treated (80M)myoblasts are shown. b, quantification of the number of foci in humanDM1myoblasts
either treated with vehicle or alkaloids at 80 M. ****, p 0.0001.
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of MBNL1 in cell lysates of treated DM1 myoblasts to
account for the reduced nuclear staining and found that
harmine in fact increased the total levels of MBNL1 in
treated DM1 myoblasts compared with vehicle-treated con-
trol DM1 myoblasts (Fig. 5, a and b). An increase in MBNL1
levels was also observed in harmine-treated WT myoblasts
(Fig. 5, c and d). 80 M berberine treatment of DM1 myo-
blasts led to a statistically insignificant increase (p  0.099)
in the number of foci to 5.8 0.9 foci per nucleus in the DM1
myoblast cell line (Fig. 4, a and b).
Identified Alkaloids Ameliorate Splicing of CLCN1 Pre-
mRNA in HSALR Mice—Next, we treated HSALR mice, a DM1
model containing a CTG250 repeat expressed under a human
skeletal actin promoter (4), with the identified alkaloids. The
compounds were tested for their ability to restore splicing of
CLCN1 (12, 13) and SERCA1 (15) pre-mRNA in quadriceps
muscle. MBNL1 promotes the exclusion of the alternatively
spliced exon 7a of the CLCN1 pre-mRNA and promotes the
inclusion of exon 22 of the SERCA1 pre-mRNA (12, 13, 15).
Vehicle-treated WT mice at the age of 10–12 weeks showed a
CLCN1 pre-mRNA exon 7a inclusion of 5.0% 0.5%, whereas,
in vehicle-treated HSALR mice, the inclusion level was elevated
to 40.9%  2.5%. The level of SERCA1 pre-mRNA exon 22
inclusion in WT mice was at 83.9%  2.9%. In HSALR mice,
exon 22 inclusion was decreased to 24.8%  2.7%. We first
tested berberine, which, at a dose of 20 mg/kg, led to reduced
activity and decreased body temperature, which urged us to
lower the dose. Treatment with 5 mg/kg and 10 mg/kg of ber-
berine did not result in any significant splicing improvement.
We then tested two close derivatives of berberine, dihydrober-
berine (DHB) and palmatine, with higher reported LD50 values.
DHB improved the splicing of the CLCN1 pre-mRNA at a dose
of 10 mg/kg by 32.5%  2.9% (p  0.0008, Student’s t test),
whereas 5 mg/kg showed no statistically significant effect (Fig.
6a). The CLCN1 splicing improvement with 10 mg/kg DHB
was confirmed by classical RT-PCR and analysis of splicing iso-
forms on a 3% agarose gel (Fig. 6d). Palmatine treatment
improved CLCN1 pre-mRNA splicing at a dose of 40 mg/kg by
34.8% 2.1% (p 0.0009) and at a dose of 25mg/kg by 25.3%
0.7% (p 0.0017), whereas 10mg/kg did not show a significant
effect (Fig. 6b). Harmine treatment at a dose of 40 mg/kg
decreased CLCN1 pre-mRNA exon 7a inclusion by 31.2% 
1.7% (p 0.0003) and did not significantly improve splicing at
a dose of 20 mg/kg (Fig. 6c). Side effects observed during
harmine treatment were transient tremors. DHB, palmatine,
and harmine had no significant effect on SERCA1 pre-mRNA
splicing (Fig. 6).
CLCN1 Protein Levels in Quadriceps Muscle of WT, HSALR,
andTreatedHSALRMice—Weexamined byWestern immuno-
blotting analysis whether the high-dose alkaloid treatments,
FIGURE 5. a, Western blot showing MBNL1 protein levels of DM1 myoblasts treated with 40 and 80 M harmine, of vehicle-treated DM1 myoblasts, and of
vehicle-treatedWTmyoblasts (left to right).b, quantificationofMBNL1band intensities normalized to laminB. Themeans of three replicates for each condition,
including the standard deviation, are shown. c, Western blot showingMBNL1 protein levels ofWTmyoblasts treatedwith vehicle or 40 and 80Mharmine (left
to right). d, quantification ofMBNL1 band intensities normalized to lamin B. Themeans of three replicates for each condition, including the standard deviation,
are shown. *, p 0.05; **, p 0.01.
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which had ameliorated CLCN1 pre-mRNA splicing, also
increased the protein levels of the full-length CLCN1 channel
in vivo. CLCN1 protein levels in quadriceps muscle of four
vehicle-treated HSALR mice were decreased by 29.1% 
12.4% (p 0.023, Student’s t test, n 4, three immunoblots)
compared with four vehicle-treatedWTmice (Fig. 7). Treat-
ment of HSALR mice with 10 mg/kg DHB raised CLCN1
protein levels by 27.1% 16.1% (p 0.095, n 4) compared
with levels of vehicle-treated HSALR mice (Fig. 7). Although
the CLCN1 protein levels of DHB-treated HSALR mice were
close to WT levels, the effect did not reach statistical signif-
icance. Both palmatine and harmine high-dose treatments of
40 mg/kg did not increase the CLCN1 protein levels in
HSALR mice (Fig. 7).
Analysis of Internalized Nuclei in GastrocnemiusMuscle Sec-
tions of Vehicle-treated WT, HSALR, and Harmine-treated
HSALRMice—Despite the very short treatment duration of only
14–16 h (two injections at a 12-h interval), we wished to exam-
ine whether the most promising small molecule, harmine, also
improved the histology in gastrocnemius muscle of harmine-
treated mice (Fig. 8). Different histological parameters were
analyzed, most importantly the percentage of fibers with inter-
FIGURE 6. Representative qPCR splicing data for vehicle-treatedWT andHSALRmice and compound-treatedHSALRmice (quadricepsmuscle). Shown
is the percentage of exon 7a (CLCN1) and exon 22 (SERCA1) pre-mRNA inclusion. The alkaloids improve the splicing of CLCN1, whereas the splicing of SERCA1
is unchanged. a, DHB treatment. b, palmatine treatment. c, harmine treatment. d, alternative splicing of the CLCN1 pre-mRNA analyzed by RT-PCR and
visualized on 3% agarose gel. Shown are two alternative splicing isoforms in vehicle-treated control mice and DHB-treated HSALR mice. **, p 0.01; ***, p
0.001.
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nalized nuclei, where no difference was detected between vehi-
cle-treated and harmine-treated HSALR mice after this short
treatment duration.
Discussion
We report the discovery of several plant-derived alkaloids as
novel bioactive small molecules with therapeutic potential for
DM1. Through inhibition of the (CUG)n-MBNL1 complex, the
alkaloids ameliorate certain aspects of the DM1 pathology. Our
screening of natural products identified the alkaloids berberine
and harmine, which were chosen for further study. Interest-
ingly, both have been described previously to bind to specific
RNA structures, such as double-stranded RNA, tRNA, and
poly(A) RNA (34–37). The berberine derivative coralyne has
been described as a complete intercalator for double-stranded
RNA and berberine as a partial intercalator (36). We therefore
hypothesize that the binding of these three aromatic alkaloids
to the double-stranded (CUG)n RNAmay involve intercalation
because of planarity. Aromatic alkaloids such as berberine,
coralyne, and harmine might be of particular interest for RNA
drug discovery, as they can interact with RNA via stacking
(intercalation), hydrogen bonding, or electrostatic interaction
(38). To our knowledge, in the context of DM1, no alkaloids
have been described so far. An in vitro screening study by Chen
et al. (28) yielded six hits of which four were alkaloids or alka-
loid derivatives of the opioid- and ergot alkaloid-type, but none
of these alkaloids could be confirmed in a secondary assay .
Berberine and harmine showed partially positive effects on
splicing and focus formation in a human DM1 cell line.
Harmine showed positive effects inmost of the studiedmodels.
It inhibited CUG78-MBNL1 complex formation in vitro and
ameliorated the pre-mRNA splicing of both the INSR exon 11
FIGURE7.a,Westernblot showingCLCN1protein levels of (i) vehicle-treatedWTmice, (ii) vehicle-treatedHSALRmice, and (iii–v) compound-treatedHSALRmice.
b, quantificationof CLCN1band intensities normalized to laminB. Themeansof four replicates for each condition, including the standarddeviation, are shown.
*, p 0.05.
FIGURE8. Shown is the analysis of internalizednuclei byH&E stainingof 8-m
mouse gastrocnemius muscle cross-sections of 10-week-old (a) vehicle-
treated WT mice, (b) vehicle-treated HSALR mice, and (c) HSALR mice after
treatment by two injections of 40 mg/kg harmine at a 12-h interval. d, quan-
titative analysis of the percentage of muscle fibers with internalized nuclei.
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andTNNT2 exon 5 in the humanDM1myoblast cell line,where
it also reduced the formation of foci without decreasing
MBNL1 protein levels. Interestingly, harmine enhanced
MBNL1-dependent alternative splicing to a comparable rela-
tive extent in both DM1 and WT myoblasts, indicating that
harmine does not act primarily via (CUG)n-MBNL1 complex
disruption but, rather, via another mechanism leading to
increased MBNL1 protein levels. We could not detect a signif-
icant difference of TNNT2 pre-mRNA splicing in myotubes
upon harmine treatment, although a trend toward MBNL1-
mediated alternative splicing was visible (data not shown).
Harmine also improved the splicing of CLCN1 pre-mRNA in
the HSALR DM1mousemodel at a high dose of 40mg/kg. Even
though 40mg/kg harmine treatment amelioratedCLCN1 splic-
ing in HSALR mice, it did not affect the histology of these mice.
This was, however, expected because of the short treatment
duration of only 14–16 h. Berberine did not perform as well as
harmine in the studied models. Although it was a stronger
CUG78-MBNL1 complex inhibitor than harmine, it only
improved the splicing of the TNNT2 pre-mRNA in the DM1
myoblast cell line, whereas the splicing of the INSR pre-mRNA
was worsened in treated DM1 myoblasts. This undesirable
splicing effect of berberine might be due to insufficient selec-
tivity of berberine for the (CUG)n RNA over the MBNL1 bind-
ing motifs in pre-mRNAs and, therefore, interference with
MBNL1-mediated splicing. MBNL1-targeted pre-mRNAs as
the toxic DMPK-(CUG)n transcripts have similar MBNL1
binding motifs (39). Interestingly, the berberine derivative
coralyne was an even stronger CUG78-MBNL1 complex inhib-
itor than berberine but showed no effect on splicing in theDM1
cell model. Coralyne is a nonspecific intercalator for double-
stranded RNA (36). Its insufficient selectivity for the (CUG)n
RNAover other double-stranded RNAsmight be the reason for
lacking specific bioactivity. Like coralyne, the two identified
diterpenequinones, methylenetanshinquinone and 1,2-dihy-
drotanshinquinone, lacked bioactivity. As the two planar diter-
penequinones were poorly water-soluble, they precipitated at
higher concentrations in the screening assay and precipitated
from solution in cell culture at concentrations of 20 and 40 M.
Among all identified compounds during our screening of nat-
ural products, planarity and aromaticity turned out to be com-
mon features, and the partly double-stranded (CUG)n RNA tar-
get selects for planar molecules with intercalating properties.
The evaluation of the alkaloids berberine, dihydroberberine,
palmatine, and harmine in the HSALR mouse model showed
promising results. Most interestingly, two alkaloids of the ber-
berine type, DHB and palmatine, and the alkaloid harmine sig-
nificantly improved the splicing of the CLCN1 pre-mRNA in
this mouse model. The alkaloid DHB was the most active alka-
loid, as it improved CLCN1 exon 7a splicing at a dose of 10
mg/kg. However, these alkaloids are not suited for therapeutic
application themselves. Their relatively low potency and toxic-
ity are issues that require medicinal chemistry optimization.
Berberine has been described as an inhibitor of complex I in the
mitochondrial respiratory chain (40). Hence, decreased meta-
bolic activity might account for the side effects we observed
upon treatmentwith berberine and its derivatives at high doses,
i.e. reduced activity and decreased body temperature. The
effect of berberine on thermoregulation in mice has been
described previously by Jiang et al. (41). In harmine-treated
mice we observed tremors after administration. Harmine has
been described as a tremorogenic substance (42). Berberine, its
derivatives DHB and palmatine, as well as harmine exert CNS
effects given that they are monoamine oxidase inhibitors (43,
44). These side effects need to be addressed bymedicinal chem-
istry modifications. However, the fact that these alkaloids pen-
etrate the blood-brain barrier stirs hope for a future small-mol-
ecule therapy that also ameliorates the DM1-associated CNS
pathology. Moreover, the identified molecules help to further
understand the characteristics of small molecules that interact
with toxic (CUG)n RNA and provide new chemical scaffolds for
medicinal chemistry studies. Particularly harmine, with its low
molecular weight of 212.25 Da, offers an appealing starting
point for chemical modifications. Harmine furthermore repre-
sents an interestingmolecule, as its biological effect is likely not
mediated only by liberation of MBNL1 from toxic (CUG)n
RNA, which was initially assumed based on results from the in
vitroCUG78-MBNL1 inhibition screening assay, but mainly via
another, yet unidentified mechanism leading to an increase in
MBNL1 protein levels in treated myoblasts. This effect will be
investigated inmore detail in follow-up studies. Our study thus
contributes to further progress in small-molecule drug discov-
ery for this disabling neuromuscular disease.
Experimental Procedures
Statistical Analysis—Unless otherwise stated, results are
expressed as mean  S.D. of n  3 independent experiments.
Comparisons between two conditions were performed using
Student’s t test with a 0.05 confidence level accepted for statis-
tical significance (*, p  0.05; **, p  0.01; ***, p  0.001; ****,
p 0.0001).
Compounds and Extracts—The compounds and extracts
screened in this study were part of natural product libraries
established at the Division of Pharmaceutical Biology of the
University of Basel. One library contained 70 pure natural com-
pounds as 10 mM solutions in DMSO, and a second library
consisted of 2128 extracts from plants and fungi archived as 10
mg/ml solutions in DMSO (32). Harmine hydrochloride was
purchased from TCI Europe (H0002). Berberine chloride
(B3251), palmatine chloride hydrate (361615), and coralyne
sulfoacetate (S424536) were obtained from Sigma-Aldrich.
Dihydroberberine (80429) was purchased from PhytoLab
GmbH. Methylenetanshinquinone (QP-393) and 1,2-dihydro-
tanshinquinone (QP-1166) were obtained from Quality Phyto-
chemicals LLC (East Brunswick, NJ). The reference substances
neomycin B (N1876), Hoechst 33258 (B2883), and mitomycin
C (M4287) were ordered from Sigma-Aldrich.
MBNL1 Preparation—MBNL1 cDNA (an isoform with
amino acids 1–382) was kindly provided by Maurice Swanson
(9) (University of Florida). The pGEX-6P-MBNL1-N-His
(amino acids 1–253) construct used in this study was cloned
according to Yuan et al. (9), and protein expression and purifi-
cation were performed similar to the procedure published by
Yuan et al. (9).MBNL1-HISwas stored in a buffer containing 10
mM Tris (pH 7.4), 50 mM NaCl, and 1 mM DTT. Protein con-
centration was determined with a NanoDrop spectrophotom-
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eter and a BCA assay (Sigma). The purity of MBNL1-HIS was
evaluated by means of SDS-PAGE followed by Coomassie
staining. MBNL1-HIS aliquots were snap-frozen in liquid
nitrogen and stored at70 °C.
CUG78 RNA Preparation—Genomic DNA was isolated
from a patient blood sample (with informed consent) with
the Puregene Blood Core Kit B (Qiagen) according to
the protocol of the manufacturer. A CTG78-containing
genomic DMPK fragment was PCR-amplified with HOT Start
DNA polymerase (Solis BioDyne) and the following primers:
DMPK forward, 5CAGCTCCAGTCCTGTGATCC3; DMPK
reverse, 5CTGGCCGAAAGAAAGAAATG3. The amplicon
was agarose gel-purified with the QIAquick gel extraction kit
(Qiagen). The purified DNA fragment was cloned by TA
cloning with the pCR II-TOPO plasmid vector in Dh5 bac-
terial cells. The plasmid was purified with the QIAprep spin
miniprep kit (Qiagen) and used as a template for PCR ampli-
fication with the following primers: T7 CUG forward,
5TAATACGACTCACTATAGGCAGCTCCAGTCCTGTG-
ATCC3; and T7 CUG reverse, 5TAATACGACTCAC-
TATAGGCTGGCCGAAAGAAAGAAATG3. The amplified
DNAwas purifiedwith theQIAquick PCRpurification kit (Qia-
gen). 200 ng of DNA was used as a template for in vitro RNA
transcription with the MEGAscript T7 transcription kit
(Ambion). CUG78 RNAwas biotin-labeled by addition of 1.875
mM biotin-14-CTP (37.5 nmol). RNA quality and purity was
tested by visualization of RNA on 8 M urea/Tris borate-EDTA
5% polyacrylamide gels.
CUG78-MBNL1 Inhibition Assay—Wash steps were per-
formed at room temperature with 150 l of wash buffer/well
(25 mM Tris (pH 7.4), 80 mM NaCl, 1 mM MgCl2, 0.5 mM DTT,
0.05% Tween 20, 1.5 mg/ml BSA, and diethylpyrocarbonate-
treated water) and incubation steps with 50 l of incubation
buffer/well (wash buffer  25 units/ml RNasin (Promega)) at
30 °C on a BIOSAN plate shaker at 300 rpm. Reacti-Bind Neu-
trAvidin-coated 96-well plates (Pierce) were prewashed once.
Wash buffer was removed, and incubation buffer containing 25
ng of biotinylated CUG78 RNA was added/well. After incuba-
tion for 1 h, the plates were washed twice. Wash buffer was
removed, and 45 l of incubation buffer containing 300 ng of
MBNL1-HIS was added, followed by addition of 5 l of 10
concentrated compound or 5 l of DMSO/water for controls.
After washing wells twice, mouse anti-HIS antibody (1:2000,
GEHealthcare, 27-4710-01) was incubated for 1 h. Twowashes
preceded 1-h incubation with goat anti-mouse-HRP antibody
(1:8000, Jackson ImmunoResearch Laboratories, 115-035-174).
After two final wash steps, 70 l of 3,3,5,5-tetramethylbenzi-
dine substrate (Thermo Scientific) was added/well at room
temperature. The colorimetric reactionwas performed at 30 °C
and 700 rpm for 3–5 min and stopped with 70 l of 0.15 M
H2SO4/well. The optical density was read at 450-nm wave-
length with aMolecular Devices plate reader. Inhibition curves
were fitted with Prism software.
HPLC-based Activity Profiling of Extracts—HPLC-based
activity profilingwas performed on aWaters 2695Alliance sep-
aration module equipped with a Waters 996 photodiode array
detector and a C18 SunFire column (3.0  150 mm, 3.5 m).
Themobile phase consisted of 0.1% formic acid in H2O (A) and
MeCN (B). A gradient of 5–100% B in 30 min was applied. The
flow rate was 0.4ml/min. 900g of extract was injected in three
portions, and time-based microfractions were collected into a
deep-well 96-well microtiter plate (29 fractions of 60 s each)
with a Gilson FC204. The microtiter plate was dried in a Gene-
vac EZ-2 evaporating system at 35 °C overnight. The dried frac-
tions were taken up in 16 l of DMSO, and 2 l was used in the
CUG78-MBNL1 inhibition assay.
Myoblast Splicing Assay—Two human fibroblast cell lines
with a doxycycline-inducible MyoD construct for differentia-
tion into myoblasts were kindly provided by Denis Furling
(Université Pierre etMarie Curie-Paris, Paris, France) (31). The
WT control cell line was derived from a 19-year-old healthy
individual with a normal CTG repeat length in the DMPK
locus, whereas the DM1 cell line was derived from an 11-year-
old individual with a CTG1300 repeat length in the same locus.
Fibroblasts were grown in growth medium (GM; 1 DMEM
with 1 GlutaMax, 10% FBS (Gibco), 30 mM HEPES, and 50
g/ml gentamycin (Sigma)) at 37 °C under 5% CO2. 50,000
cells/well were seeded in 6-well plates and grown for 3 days.
Cells were washed with 1 DMEM, and then differentiation
medium (GMwith 5 g/ml doxycycline) was added. After 24 h
in differentiation medium, the cells were washed with 1
DMEMand treated for 24 hwith either compound orDMSO in
differentiation medium. The cells were washed with 1 PBS,
and total RNA was extracted with TRI reagent (Sigma)
according to the protocol of the manufacturer. 500 ng of
RNA was used for reverse transcription with the SuperScript
III first-strand synthesis system for RT-RCR (Invitrogen),
according to the protocol of the manufacturer with random
hexamer primers. Pre-mRNA targets were chosen based on
prior studies of small molecules in cellular and in vivo mod-
els of DM1 (21). 1 l of cDNA was used for qPCR with 40
amplification cycles of 15 s at 95 °C, 15 s at 61 °C, and 20 s at
72 °C. qPCR was performed with two primer pairs, one
primer pair only amplifying splicing variants that contain an
investigated alternative exon and the other primer pair
amplifying all possible splicing variants (pan): INSR, 5GAC-
CTGGTCTCCACCATTCG3 (forward), 5CACCAGTGC-
CTGAAGAGGTT3 (reverse exon), and 5ACGAAAAC-
CACGTTGTGCAG3 (reverse pan); TNNT2, 5CAGCTG-
CTGTTCTGAGGGAG3 (forward), 5CTGCTCGTCTTC-
GTCCTCTC3 (reverse exon), and 5CCTCGTACTCTTC-
CACCACC3 (reverse pan). -ACTIN was used as a control
gene with the following primers: forward, 5CCAACCGC-
GAGAAGATGA3; reverse, 5CCAGAGGCGTACAGGG-
ATAG3. MBNL1-independent splicing of ATE1 and FHL1
(33) was analyzed using the following primers: ATE1,
5GGGTTTCCAGGCTCAAGGTC3 (forward), 5TGAACT-
GCGAACTTGGTGGA3 (reverse exon), and 5TGTGTGAT-
GCATTCTCTGGTAA3 (reverse pan); FHL1, 5ATGC-
CGATTGCTTTGTGTGT3 (forward), 5CTGGGTGGC-
TCACTCTTGAC3 (reverse exon), and 5TCTTGCATC-
CAGCACACTTCT3 (reverse pan). Amplification was done
withHOTFIREPol EvaGreen qPCRmixture (Solis BioDyne) on
an Applied Biosystems StepOnePlus real-time PCR machine.
The amount of the splicing variant, including the investigated
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alternative exon, was quantified relative to the amount of the
pan-amplicon, which gave a percentage of exon inclusion.
For classical RT-PCR, 1 l of cDNA was used for PCR with 40
amplification cycles of 15 s at 95 °C, 15 s at 61 °C, and 20 s at 72 °C.
The following primer pairs were used: INSR, 5CCAAAGAC-
AGACTCTCAGAT3 (forward) and 5AACATCGCCAA-
GGGACCTGC3 (reverse); TNNT2, 5ATAGAAGAGGTG-
GTGGAAGAGTAC3 (forward) and 5GTCTCAGCCTC-
TGCTTCAGCATCC3 (reverse). Amplificationwas donewith
HOT Start DNA polymerase (Solis BioDyne) on an Applied
Biosystems PCR machine. The PCR products were run on 3%
agarose gels stained with RedSafe (iNtRON). Gels were imaged
with a Gel Doc XR (Bio-Rad).
Myoblast Viability Assay—C2C12 mouse myoblasts were
plated in 96-well plates inGM (4000 cells/well, 100l/well) and
grown overnight. Compounds/DMSOwere then added in GM.
After incubation for 48 h, the CellTiter-Blue reagent (Pro-
mega) was added according to the protocol of the manufac-
turer. Fluorescence was measured with an Infinite F500 plate
reader (Tecan) with an excitation/emission wavelength of 535/
590 nm. Signal concentration curves were fitted with Prism
software to determine toxicity IC50 values.
FISHand Immunofluorescence—15,000 fibroblasts/well were
grown for 24 h in GM on 0.3% gelatin-coated coverslips (24-
well dishes). Cells were washed with 1 DMEM and differen-
tiated in DM for 24 h. Washing with 1 DMEM preceded the
compound/vehicle incubation in DM for 24 h. Coverslip wash-
ing, permeabilization of myoblasts, FISH and immunostaining
withMBNL1 antibody (A2764, a kind gift fromCharles Thorn-
ton, University of Rochester) was performed according to the
procedure of Warf et al. (21). Wash buffer I contained 1 PBS
and 0.05% Triton X-100. Coverslips were blocked in buffer
(wash buffer I and 3% BSA, 15 min, room temperature) before
MBNL1 antibody incubation. 1:750 diluted goat anti-rabbit
DyLight 488 antibody (Jackson ImmunoResearch Laboratories,
111-485-144) was added in wash buffer I (1 h, room tempera-
ture). Myoblasts were stained with 1:20,000 DAPI in wash
buffer I (5 min, room temperature). Coverslips were mounted
on glass slides with FluorSave reagent (Calbiochem). Cells were
imaged using a Leica DMRE fluorescence microscope. For
quantification, the amount of foci was counted for 3 50 ran-
domly chosen nuclei from three experiments.
Treatment of Mice—HSALR transgenic mice in line 20b were
kindly provided by C. Thornton. FVB/N (WT) control mice
were obtained from the animal facility of the Department of
Biomedicine, University Hospital Basel, Switzerland. Age- and
gender-matched groups of a minimum of three mice (10–12
weeks old, male) of WT or HSALR mice were treated by two
intraperitoneal injections of compound/vehicle (12-h interval).
Harmine hydrochloride was administered in saline and berber-
ine chloride, dihydroberberine, and palmatine chloride hydrate
in 5% DMSO/PBS. Mice were sacrificed 2–4 h after the second
injection. Dissected quadriceps muscle was powdered after
freezing in liquid nitrogen. Animal studies were conducted in
accordance with the Animal Research Authorities (Canton
Basel-Stadt, Switzerland, permit no. 2632).
Mouse Skeletal Muscle Splicing Assay—Powdered quadri-
ceps muscle tissue was taken up in TRI reagent (Sigma) and
was grinded with a Polytron (Kinematica) for 30 s at 4 °C.
Insoluble material was removed by centrifugation at 12,000
rpm (10 min, 4 °C). From the supernatant, RNA was
extracted with TRI reagent (Sigma) according to the proto-
col of the manufacturer. The qPCR amplification protocol
was analogous to the myoblast qPCR protocol with the
following primer pairs: CLCN1, 5GGGCGTGGGATGC-
TACTTTG3 (forward exon), 5CTGACATCCTGACAG-
TGGGC3 (forward pan), and 5AGGACACGGAACAC-
AAAGGC3 (reverse); SERCA1, 5GCCCTGGACTTTACC-
CAGTG3 (forward), 5ACGGTTCAAAGACATGGAGGA3
(reverse exon), and 5CCTCCAGATAGTTCCGAGCA3
(reverse pan). Pre-mRNA targets were chosen based on prior
studies of small molecules in cellular and in vivo models of
DM1 (21). Classical RT-PCR was performed analogously to
the myoblast splicing assay with the following primers:
CLCN1, 5GGAATACCTCACACTCAAGGCC3 (forward)
and 5CACGGAACACAAAGGCACTGAATGT3 (reverse);
SERCA1, 5GCTCATGGTCCTCAAGATCTCAC3 (forward)
and 5GGGTCAGTGCCTCAGCTTTG3 (reverse).
Western Blotting Detection of CLCN1 Protein from Mouse
Skeletal Muscle—Proteins were extracted from powdered
mouse quadriceps muscle according to Dimauro et al. (45) to
obtain the nuclear/membrane fraction. Instead of NET, radio-
immunoprecipitation assay buffer (50mMTris HCL (pH 8.0),
150mMNaCl, 1%Nonidet P-40, 0.5% sodium deoxycholate, 1%
TritonX-100, 0.1%SDS, and 10%glycerol)was used, containing
protease and phosphatase inhibitor tablets (Roche). Protein
concentrations were determined with a BCA assay (Sigma).
10-g samples were separated by Tris/glycine SDS-PAGE on
8% gels and analyzed by Western blotting using Protran BA85
nitrocellulose membranes (GE Healthcare), rabbit polyclonal
antibody against the N terminus of full-length CLCN1 (1:1000,
a kind gift from Thomas Cooper, Baylor College of Medicine)
(13), and HRP-tagged goat anti-rabbit secondary antibody
(1:10000, Jackson ImmunoResearch Laboratories, 111-035-
003). To detect lamin B (loading control), goat polyclonal anti-
lamin B antibody (1:1000, Santa Cruz Biotechnology, sc-6216)
andHRP-tagged swine anti-goat antibody (1:10,000, Life Tech-
nologies, ACI3404) were used. All antibodies were incubated in
1 TBS, 3% BSA, 0.1% Tween 20, and 0.08% SDS. Membranes
were incubated for 5min with LumiGLO (KPL) chemilumines-
cent substrate and exposed to Super RX films (Fuji).
Western Blotting Detection of MBNL1 Protein from Myo-
blasts—Human fibroblasts were cultured, differentiated into
myoblasts, and treated in 6-well plates as described above for
the myoblast splicing assay. Myoblasts were washed with 1
PBS, harvested in 1 PBS, and centrifuged for 10 min at 4 °C
and 15,000 rpm, and then the pellet was resuspended in 100 l
of radioimmune precipitation assay buffer containing prote-
ase and phosphatase inhibitor tablets (Roche). After 2-h incu-
bation on a wheel at 4 °C, the samples were centrifuged for 10
min at 4 °C and 12,000 rpm. Protein concentrations in super-
natantswere determinedwith a BCAassay (Sigma). 10-g sam-
ples were separated by Tris/glycine SDS-PAGE on 12% gels.
Western blotting was performed as described above using
1:5000 diluted A2764 anti-MBNL1 antibody and anti-rabbit
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secondary antibody (1:10,000, Jackson ImmunoResearch Labo-
ratories, 111-035-003).
Histological Analysis of Internalized Nuclei—8-m cryostat
cross-sections from gastrocnemius mouse muscle were stained
withH&E and analyzed for the percentage ofmuscle fibers with
internalized nuclei.
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